Carolina Eye Participates in National Study
June 16th, 2015 by Carolina Eye Associates
Carolina Eye Hosts Clinical Study for Wet Age-Related Macular Degeneration
Doctors Gregory Mincey and Arghavan Almony, diabetic eye, retina and vitreous specialists will be participating in a national clinical study comparing the efficacy and safety of a new treatment for neovascular age-related macular degeneration (“wet AMD”). This will be a two-year, randomized, double-masked, and multi-center, three-arm study comparing the efficacy and safety of RTH258 verses Aflibercept in people with wet AMD.
Dr. Almony states, “Carolina Eye is committed to addressing patients’ needs in retina and hopes to improve visual outcomes in patients with wet age-related macular degeneration. The principal aim of treatment of neovascular AMD is to preserve visual acuity and to reduce the risk of additional severe vision loss for as long as possible. This goal can be accomplished by destroying the choroidal neovascularization without causing damage to the retina, thereby reducing the likelihood of progressive destructive scarring of the retina overlying and surrounding the central part of vision.”
AMD is a leading cause of severe vision loss in people over age 50, and impacts 25 to 30 million people worldwide. AMD occurs when the center of the retina, known as the macula, deteriorates leading to gradual loss in central vision.
Study subjects must be at least 50 years of age with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.
If you think you may be a candidate for this study or have a patient who meets the criteria described above, please contact Carolina Eye Associates, Lisa Fulghum, Clinical Trials Coordinator, 910-295-2100 ext. 881 or firstname.lastname@example.org.
Comments are closed.